PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $88,000 | +8.6% | 10,891 | 0.0% | 0.19% | +20.1% |
| Q1 2018 | $81,000 | -37.7% | 10,891 | -50.0% | 0.16% | +42.0% |
| Q4 2017 | $130,000 | -18.8% | 21,782 | 0.0% | 0.11% | -22.2% |
| Q3 2017 | $160,000 | +8.1% | 21,782 | 0.0% | 0.14% | +5.9% |
| Q2 2017 | $148,000 | -64.0% | 21,782 | -50.0% | 0.14% | -55.4% |
| Q1 2017 | $411,000 | – | 43,565 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |